A Rare Adverse Drug Reaction of Imatinib Mesylate
نویسندگان
چکیده
منابع مشابه
Imatinib mesylate: A designer drug.
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positiv...
متن کاملCutaneous adverse effects of imatinib mesylate
A 52-year -old female patient was found to have elevated white blood cell count (WBC) on routine physical examination. Her WBC count was 67.260/ uL, hemoglobin was 8.3 gm/dL, hematocrit was 26.1% and platelet count was 133,000/uL. Bone marrow reveled myeloid hyperplasia and the Philadelphia chromosome was positive. Patient was diagnosed as chronic myeloid leukemia (CML) and imatinib mesylate tr...
متن کاملGynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
BACKGROUND Imatinib mesylate has been the standard therapeutic treatment for chronic myeloid leukemia, advanced and metastatic gastrointestinal stromal tumor (GIST). It is well tolerated with mild adverse effects. Gynecomastia development during the course of treatment has been rarely reported. METHODS Ninety-eight patients with advanced or recurrent GIST were treated with imatinib mesylate. ...
متن کاملImatinib mesylate-induced lichenoid drug eruption.
Imatinib mesylate (imatinib) is a tyrosine kinase inhibitor initially approved by the US Food and Drug Administration in 2001 for chronic myeloid leukemia (CML). Since then, the number of indicated uses for imatinib has substantially increased. It is increasingly important that dermatologists recognize adverse cutaneous manifestations of imatinib and are aware of their management and outcomes t...
متن کاملDrug- Induced Pneumonitis: A Rare Complication of Imatinib Mesylate Therapy in Patients with Chronic Myeloid Leukemia
Therapy by drugs that block the activity of the protein Bcr-Abl, specific inhibitors of Bcr-Abl tyrosine kinase (TKI), significantly changed the prognosis of chronic myeloid leukemia (CML). Bcr-Abl gene is located on the Philadelphia chromosome (Ph'-chromosome), resulting from t(9;22) translocation, plays a key role in the onset and progression of CML. To date, the standard in the treatment of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Medical and Paediatric Oncology
سال: 2019
ISSN: 0971-5851,0975-2129
DOI: 10.4103/ijmpo.ijmpo_56_18